Drug Profile


Alternative Names: PP 56

Latest Information Update: 01 Aug 2000

Price : $50

At a glance

  • Originator Perstorp
  • Class Peptides
  • Mechanism of Action Neuropeptide inhibitors; Neuropeptide Y receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atherosclerosis; Diabetic complications; Heart failure; Hypertension; Pain; Thrombosis

Most Recent Events

  • 01 Aug 2000 Discontinued-Preclinical for Thrombosis (Unknown route)
  • 01 Aug 2000 Discontinued-Preclinical for Pain in Sweden (Unknown route)
  • 01 Aug 2000 Discontinued-Preclinical for Heart failure (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top